Overview

Gender

male

Dr. Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2011.
Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a private biotechnology company. Dr. Siegall is an author on more than 70 publications and holds 15 patents.
He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.